Company · CIK 0000818033 · SIC 2834 — Pharmaceutical Preparations · Nasdaq
HERON THERAPEUTICS, INC. /DE/ · HRTX
Insider activity reported against this company. All insider holders · On EDGAR ↗
Reported at this company — common stock
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 6, 2026 FMForm 4 → | Aug 10, 10:18 am EDT | Mark Earl HensleyChief Operating Officer | 40,138 | $0.50 | $4,444 | 170,901 | — | |
| Jul 31, 2026 MForm 4 → | Aug 3, 11:20 am EDT | Mark Earl HensleyChief Operating Officer | 11,769 | — | — | 148,539 | — | |
| Jul 30, 2026 FMForm 4 → | Aug 3, 10:59 am EDT | William P ForbesEVP, Chief Development Officer | 30,137 | $0.50 | $3,337 | 241,173 | — | |
| Jul 30, 2026 FMForm 4 → | Aug 3, 9:50 am EDT | Ira DuarteEVP, Chief Financial Officer | 32,405 | $0.50 | $3,588 | 281,899 | — | |
| Jul 30, 2026 MForm 4 → | Aug 3, 9:32 am EDT | Craig A CollardChief Executive Officer, Director | 84,810 | — | — | 856,492 | — | |
| Jul 19, 2026 MForm 4 → | Jul 20, 4:22 pm EDT | Craig A CollardChief Executive Officer, Director | 13,797 | — | — | 771,682 | — | |
| Jul 19, 2026 FMForm 4 → | Jul 20, 4:10 pm EDT | William P ForbesEVP, Chief Development Officer | 4,975 | $0.47 | $517 | 224,384 | — | |
| Jul 19, 2026 FMForm 4 → | Jul 20, 3:54 pm EDT | Ira DuarteEVP, Chief Financial Officer | 4,975 | $0.47 | $517 | 263,846 | — | |
| Jun 16, 2026 FMForm 4 → | Jun 17, 10:52 am EDT | Ira DuarteEVP, Chief Financial Officer | 16,055 | $0.38 | $1,351 | 261,073 | — | |
| Jun 6, 2026 MForm 4 → | Jun 8, 10:27 am EDT | William P ForbesEVP, Chief Development Officer | 12,500 | — | — | 221,611 | — | |
| Dec 7, 2018 GForm 5 → | Feb 14, 2019, 4:02 pm EST | Kevin C TangDirector | 77,119 | — | — | 5,753,096 | — | plan? |
| Nov 2, 2018 SForm 4 → | Nov 2, 9:17 pm EDT | Kimberly ManhardExecutive VP, Drug Development | 494 | $30.62 | $15,125 | 0 | −100% | plan? |
| Oct 31, 2018 JForm 4 → | Nov 2, 9:17 pm EDT | Kimberly ManhardExecutive VP, Drug Development | 494 | $23.60 | $11,656 | 494 | — | plan? |
| Oct 1, 2018 SForm 4 → | Oct 2, 9:12 pm EDT | Kimberly ManhardExecutive VP, Drug Development | 6,000 | $32.07 | $192,433 | 0 | −100% | plan? |
| Oct 1, 2018 MForm 4 → | Oct 2, 9:12 pm EDT | Kimberly ManhardExecutive VP, Drug Development | 6,000 | $13.00 | $78,000 | 6,000 | — | plan? |
| Sep 14, 2018 MForm 4 → | Sep 14, 11:41 am EDT | Barry D QuartChief Executive Officer, Director | 19,675 | $7.20 | $141,660 | 89,275 | — | plan? |
| Sep 12, 2018 SForm 4 → | Sep 12, 12:28 pm EDT | Kevin C Tang +2Director, 10% Owner | 2,695,000 | $35.75 | $96,346,250 | 5,830,215 | −31.6% | plan? |
| Jul 2, 2018 SForm 4 → | Jul 3, 9:05 pm EDT | Kimberly ManhardExecutive VP, Drug Development | 6,000 | $37.53 | $225,179 | 0 | −100% | plan? |
| Jul 2, 2018 MForm 4 → | Jul 3, 9:05 pm EDT | Kimberly ManhardExecutive VP, Drug Development | 6,000 | $13.00 | $78,000 | 6,000 | — | plan? |
| Jul 2, 2018 SForm 4 → | Jul 3, 9:03 pm EDT | Robert HoffmanCFO & SVP, Finance | 30,000 | $38.17 | $1,145,230 | 1,280 | −95.9% | plan? |
| Jun 29, 2018 SForm 4 → | Jul 3, 9:01 pm EDT | Robert RosenPresident, Director | 225,000 | $38.98 | $8,769,818 | 2,640 | −98.8% | plan? |
| Jun 29, 2018 MForm 4 → | Jul 3, 9:01 pm EDT | Robert RosenPresident, Director | 225,000 | $7.20 | $1,620,000 | 98,171 | — | plan? |
| Jun 21, 2018 SForm 4 → | Jun 22, 9:35 pm EDT | Barry D QuartChief Executive Officer, Director | 50,000 | $39.05 | $1,952,500 | 69,600 | −41.8% | plan? |
| Apr 30, 2018 JMForm 4 → | Jul 3, 9:03 pm EDT | Robert HoffmanCFO & SVP, Finance | 30,744 | $15.25 | $468,834 | 31,280 | — | plan? late |
| Apr 30, 2018 JMForm 4 → | Jun 22, 9:35 pm EDT | Barry D QuartChief Executive Officer, Director | 51,607 | $9.18 | $473,741 | 119,600 | — | plan? late |
| Mar 29, 2018 PForm 4 → | Apr 2, 4:01 pm EDT | Kevin C Tang +2Director, 10% Owner | 192,308 | $26.00 | $5,000,008 | 8,525,215 | +2.31% | plan? |
| Mar 19, 2018 SForm 4 → | Mar 19, 7:24 pm EDT | Kimberly ManhardExecutive VP, Drug Development | 18,000 | $30.00 | $540,000 | 0 | −100% | plan? |
| Mar 19, 2018 MForm 4 → | Mar 19, 7:24 pm EDT | Kimberly ManhardExecutive VP, Drug Development | 18,000 | $13.00 | $234,000 | 18,000 | — | plan? |
| Mar 19, 2018 SForm 4 → | Mar 19, 7:22 pm EDT | Barry D QuartChief Executive Officer, Director | 100,000 | $29.75 | $2,975,000 | 67,993 | −59.5% | plan? |
| Mar 19, 2018 MForm 4 → | Mar 19, 7:22 pm EDT | Barry D QuartChief Executive Officer, Director | 100,000 | $7.20 | $720,000 | 167,993 | — | plan? |
| Mar 14, 2018 SForm 4 → | Mar 16, 9:00 pm EDT | Barry D QuartChief Executive Officer, Director | 100,000 | $24.75 | $2,475,000 | 67,993 | −59.5% | plan? |
| Mar 14, 2018 MForm 4 → | Mar 16, 9:00 pm EDT | Barry D QuartChief Executive Officer, Director | 100,000 | $7.20 | $720,000 | 167,993 | — | plan? |
| Jan 10, 2018 SForm 4 → | Jan 12, 4:21 pm EST | Kimberly ManhardExecutive VP, Drug Development | 7,584 | $20.00 | $151,680 | 0 | −100% | plan? |
| Jan 10, 2018 MForm 4 → | Jan 12, 4:21 pm EST | Kimberly ManhardExecutive VP, Drug Development | 7,584 | $13.00 | $98,592 | 7,584 | — | plan? |
| Oct 31, 2017 JForm 4 → | Dec 20, 4:13 pm EST | Robert HoffmanCFO & SVP, Finance | 536 | $13.05 | $6,993 | 536 | — | plan? late |
| Apr 28, 2017 JForm 4 → | Dec 20, 4:15 pm EST | Barry D QuartChief Executive Officer, Director | 1,684 | $12.62 | $21,256 | 67,993 | — | plan? late |
| Apr 24, 2017 SForm 4 → | Apr 24, 8:58 pm EDT | Kimberly ManhardExecutive VP, Drug Development | 21,542 | $15.33 | $330,263 | 0 | −100% | plan? |
| Apr 24, 2017 MForm 4 → | Apr 24, 8:58 pm EDT | Kimberly ManhardExecutive VP, Drug Development | 21,542 | $8.99 | $193,643 | 21,542 | — | plan? |
| Jan 19, 2017 PForm 4 → | Jan 23, 4:29 pm EST | John PoyhonenDirector | 10,000 | $12.20 | $122,000 | 10,000 | — | plan? |
| Jan 19, 2017 PForm 4 → | Jan 23, 4:03 pm EST | Kevin C Tang +2Director, 10% Owner | 2,459,016 | $12.20 | $29,999,995 | 8,332,907 | +41.9% | plan? |
| Aug 10, 2016 SForm 4 → | Aug 12, 5:14 pm EDT | Robert RosenPresident & CCO, Director | 100,000 | $23.30 | $2,329,895 | 2,640 | −97.4% | plan? |
| Aug 10, 2016 MForm 4 → | Aug 12, 5:14 pm EDT | Robert RosenPresident & CCO, Director | 100,000 | $7.20 | $720,000 | 102,640 | — | plan? |
| Jun 16, 2016 FMForm 4 → | Jun 20, 8:01 pm EDT | Kevin C Tang +2Director, 10% Owner | 1,493,639 | $6.03 | $9,000,012 | 5,873,891 | — | plan? |
| Apr 29, 2016 JForm 4 → | Dec 23, 4:03 pm EST | Brian G. DrazbaVP, Finance & CFO | 1,115 | $15.52 | $17,306 | 3,798 | — | plan? late |
| Apr 29, 2016 JMForm 4 → | Jul 20, 8:50 am EDT | Barry D QuartChief Executive Officer, Director | 5,467 | $8.89 | $48,589 | 66,309 | — | plan? late |
| Apr 19, 2016 SForm 4 → | Apr 21, 9:27 pm EDT | Robert RosenPresident, Director | 200,000 | $23.23 | $4,646,423 | 2,640 | −98.7% | plan? |
| Apr 19, 2016 MForm 4 → | Apr 21, 9:27 pm EDT | Robert RosenPresident, Director | 200,000 | $7.20 | $1,440,000 | 22,302 | — | plan? |
| Mar 21, 2016 MForm 4 → | Mar 23, 3:07 pm EDT | Paul MarshallSVP, Technical Operations | 1,100 | $9.05 | $9,955 | 2,200 | — | plan? |
| Mar 2, 2016 MForm 4 → | Mar 3, 8:01 am EST | Barry D QuartChief Executive Officer, Director | 3,472 | $7.20 | $24,998 | 60,842 | — | plan? |
| Dec 29, 2015 GForm 5 → | Feb 12, 2016, 5:04 pm EST | Barry D QuartChief Executive Officer, Director | 25,000 | — | — | 57,370 | — | plan? |
| Dec 29, 2015 MForm 4 → | Dec 30, 5:14 pm EST | Paul MarshallSVP, Technical Operations | 1,100 | $9.05 | $9,955 | 1,100 | — | plan? |
| Dec 28, 2015 MForm 4 → | Dec 30, 5:13 pm EST | Barry D QuartChief Executive Officer, Director | 2,315 | $7.20 | $16,668 | 82,370 | — | plan? |
| Oct 14, 2015 MForm 4 → | Oct 15, 8:02 am EDT | Barry D QuartChief Executive Officer, Director | 10,000 | $7.20 | $72,000 | 80,055 | — | plan? |
| Sep 29, 2015 MForm 4 → | Sep 30, 8:51 am EDT | Barry D QuartChief Executive Officer, Director | 14,306 | $7.20 | $103,003 | 70,055 | — | plan? |
| Jun 10, 2015 PForm 4 → | Jun 12, 4:06 pm EDT | Kevin C Tang +2Director, 10% Owner | 121,212 | $24.75 | $2,999,997 | 4,867,530 | +2.55% | plan? |
| Jun 1, 2015 SForm 4 → | Jun 3, 6:46 pm EDT | Kimberly ManhardDirector | 13,208 | $23.09 | $304,918 | 0 | −100% | plan? |
| Jun 1, 2015 MForm 4 → | Jun 3, 6:46 pm EDT | Kimberly ManhardDirector | 13,208 | $8.85 | $116,907 | 10,500 | — | plan? |
| May 29, 2015 PForm 4 → | Jun 2, 4:01 pm EDT | Kevin C Tang +2Director, 10% Owner | 150,000 | $20.62 | $3,092,285 | 4,746,318 | +3.26% | plan? |
| Apr 30, 2015 JForm 4 → | Dec 24, 12:29 pm EST | Brian G. DrazbaVP, Finance & CFO | 1,865 | $8.27 | $15,428 | 2,683 | — | plan? late |
| Apr 30, 2015 JMForm 4 → | Aug 19, 4:39 pm EDT | Barry D QuartChief Executive Officer, Director | 12,881 | $7.29 | $93,896 | 55,749 | — | plan? late |
| Mar 5, 2015 SForm 4 → | Mar 9, 7:02 pm EDT | Paul MarshallSVP, Technical Operations | 70,000 | $14.69 | $1,028,000 | 0 | −100% | plan? |
| Mar 5, 2015 MForm 4 → | Mar 9, 7:02 pm EDT | Paul MarshallSVP, Technical Operations | 70,000 | $9.40 | $658,000 | 70,000 | — | plan? |
| Mar 2, 2015 SForm 4 → | Mar 4, 6:52 pm EST | Barry D QuartChief Executive Officer, Director | 10,000 | $13.07 | $130,727 | 42,868 | −18.9% | plan? |
| Apr 29, 2014 SForm 5 → | Feb 12, 2015, 2:04 pm EST | SPCH, LLC +1Other | 16,000 | $10.78 | $172,518 | 79,238 | −16.8% | plan? |
| Mar 12, 2014 SForm 5 → | Feb 12, 2015, 4:35 pm EST | Savitr Capital, LLCOther | 97,157 | $12.85 | $1,248,261 | 1,712,366 | −5.37% | plan? |
Reported at this company — derivatives (options, RSUs, warrants)
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 6, 2026 MForm 4 → | Aug 10, 10:18 am EDT | Mark Earl HensleyChief Operating Officer | 31,250 | — | — | 343,750 | — | |
| Jul 31, 2026 MForm 4 → | Aug 3, 11:20 am EDT | Mark Earl HensleyChief Operating Officer | 11,769 | — | — | 164,776 | — | |
| Jul 30, 2026 MForm 4 → | Aug 3, 10:59 am EDT | William P ForbesEVP, Chief Development Officer | 23,463 | — | — | 116,944 | — | |
| Jul 30, 2026 MForm 4 → | Aug 3, 9:50 am EDT | Ira DuarteEVP, Chief Financial Officer | 25,229 | — | — | 116,944 | — | |
| Jul 30, 2026 MForm 4 → | Aug 3, 9:32 am EDT | Craig A CollardChief Executive Officer, Director | 84,810 | — | — | 347,886 | — | |
| Jul 19, 2026 MForm 4 → | Jul 20, 4:22 pm EDT | Craig A CollardChief Executive Officer, Director | 13,797 | — | — | 82,781 | — | |
| Jul 19, 2026 MForm 4 → | Jul 20, 4:10 pm EDT | William P ForbesEVP, Chief Development Officer | 3,874 | — | — | 23,246 | — | |
| Jul 19, 2026 MForm 4 → | Jul 20, 3:54 pm EDT | Ira DuarteEVP, Chief Financial Officer | 3,874 | — | — | 23,246 | — | |
| Jun 16, 2026 MForm 4 → | Jun 17, 10:52 am EDT | Ira DuarteEVP, Chief Financial Officer | 12,500 | — | — | 12,500 | — | |
| Jun 6, 2026 MForm 4 → | Jun 8, 10:27 am EDT | William P ForbesEVP, Chief Development Officer | 12,500 | — | — | 12,500 | — | |
| Dec 15, 2018 AForm 4 → | Dec 18, 8:09 pm EST | Robert RosenPresident, Director | 300,000 | — | — | 300,000 | — | |
| Dec 15, 2018 AForm 4 → | Dec 18, 8:09 pm EST | Barry D QuartChief Executive Officer, Director | 300,000 | — | — | 300,000 | — | |
| Dec 15, 2018 AForm 4 → | Dec 18, 8:08 pm EST | Kimberly ManhardExecutive VP, Drug Development | 100,000 | — | — | 100,000 | — | |
| Dec 15, 2018 AForm 4 → | Dec 18, 8:07 pm EST | Robert HoffmanCFO & SVP, Finance | 71,000 | — | — | 71,000 | — | |
| Dec 15, 2018 AForm 4 → | Dec 18, 8:06 pm EST | Waage ChristianDirector | 17,000 | — | — | 17,000 | — | |
| Dec 15, 2018 AForm 4 → | Dec 18, 8:06 pm EST | John PoyhonenDirector | 49,500 | — | — | 30,000 | — | |
| Dec 15, 2018 AForm 4 → | Dec 18, 8:05 pm EST | Craig A JohnsonDirector | 21,000 | — | — | 21,000 | — | |
| Dec 15, 2018 AForm 4 → | Dec 18, 5:57 pm EST | Kevin C TangDirector, 10% Owner | 17,000 | — | — | 17,000 | — | |
| Oct 1, 2018 MForm 4 → | Oct 2, 9:12 pm EDT | Kimberly ManhardExecutive VP, Drug Development | 6,000 | — | — | 82,416 | — | |
| Sep 14, 2018 MForm 4 → | Sep 14, 11:41 am EDT | Barry D QuartChief Executive Officer, Director | 19,675 | — | — | 710,601 | — | |
| Jul 2, 2018 MForm 4 → | Jul 3, 9:05 pm EDT | Kimberly ManhardExecutive VP, Drug Development | 6,000 | — | — | 88,416 | — | |
| Jul 2, 2018 MForm 4 → | Jul 3, 9:03 pm EDT | Robert HoffmanCFO & SVP, Finance | 30,000 | — | — | 100,000 | — | |
| Jun 29, 2018 MForm 4 → | Jul 3, 9:01 pm EDT | Robert RosenPresident, Director | 225,000 | — | — | 600,000 | — | |
| Jun 21, 2018 MForm 4 → | Jun 22, 9:35 pm EDT | Barry D QuartChief Executive Officer, Director | 50,000 | — | — | 250,000 | — | |
| Mar 19, 2018 MForm 4 → | Mar 19, 7:24 pm EDT | Kimberly ManhardExecutive VP, Drug Development | 18,000 | — | — | 94,416 | — | |
| Mar 19, 2018 MForm 4 → | Mar 19, 7:22 pm EDT | Barry D QuartChief Executive Officer, Director | 100,000 | — | — | 730,276 | — | |
| Mar 14, 2018 MForm 4 → | Mar 16, 9:00 pm EDT | Barry D QuartChief Executive Officer, Director | 100,000 | — | — | 830,276 | — | |
| Jan 10, 2018 MForm 4 → | Jan 12, 4:21 pm EST | Kimberly ManhardExecutive VP, Drug Development | 7,584 | — | — | 112,416 | — | |
| Dec 18, 2017 AForm 4 → | Dec 20, 4:18 pm EST | Waage ChristianDirector | 17,000 | — | — | 17,000 | — | |
| Dec 18, 2017 AForm 4 → | Dec 20, 4:18 pm EST | John PoyhonenDirector | 19,500 | — | — | 19,500 | — | |
| Dec 18, 2017 AForm 4 → | Dec 20, 4:17 pm EST | Craig A JohnsonDirector | 21,000 | — | — | 21,000 | — | |
| Dec 18, 2017 AForm 4 → | Dec 20, 4:16 pm EST | Kevin C TangDirector, 10% Owner | 17,000 | — | — | 17,000 | — | |
| Dec 18, 2017 AForm 4 → | Dec 20, 4:16 pm EST | Robert RosenPresident, Director | 310,000 | — | — | 310,000 | — | |
| Dec 18, 2017 AForm 4 → | Dec 20, 4:15 pm EST | Barry D QuartChief Executive Officer, Director | 310,000 | — | — | 310,000 | — | |
| Dec 18, 2017 AForm 4 → | Dec 20, 4:14 pm EST | Kimberly ManhardExecutive VP, Drug Development | 120,000 | — | — | 120,000 | — | |
| Dec 18, 2017 AForm 4 → | Dec 20, 4:13 pm EST | Robert HoffmanCFO & SVP, Finance | 56,667 | — | — | 56,667 | — | |
| Apr 24, 2017 MForm 4 → | Apr 24, 8:58 pm EDT | Kimberly ManhardExecutive VP, Drug Development | 21,542 | — | — | 0 | — | |
| Apr 24, 2017 AForm 4 → | Apr 24, 8:54 pm EDT | Robert HoffmanCFO & SVP, Finance | 130,000 | — | — | 130,000 | — | |
| Apr 5, 2017 AForm 4 → | Apr 7, 4:28 pm EDT | Waage ChristianDirector | 1,125 | — | — | 1,125 | — | |
| Dec 21, 2016 AForm 4 → | Dec 23, 4:08 pm EST | Waage ChristianDirector | 15,500 | — | — | 15,500 | — | |
| Dec 21, 2016 AForm 4 → | Dec 23, 4:07 pm EST | John PoyhonenDirector | 19,500 | — | — | 19,500 | — | |
| Dec 21, 2016 AForm 4 → | Dec 23, 4:06 pm EST | Craig A JohnsonDirector | 21,000 | — | — | 21,000 | — | |
| Dec 21, 2016 AForm 4 → | Dec 23, 4:05 pm EST | Robert RosenPresident, Director | 310,000 | — | — | 310,000 | — | |
| Dec 21, 2016 AForm 4 → | Dec 23, 4:04 pm EST | Barry D QuartChief Executive Officer, Director | 310,000 | — | — | 310,000 | — | |
| Dec 21, 2016 AForm 4 → | Dec 23, 4:04 pm EST | Kevin C TangDirector, 10% Owner | 17,000 | — | — | 17,000 | — | |
| Dec 21, 2016 AForm 4 → | Dec 23, 4:03 pm EST | Kimberly ManhardExecutive VP, Drug Development | 120,000 | — | — | 120,000 | — | |
| Oct 7, 2016 AForm 4 → | Oct 7, 9:01 pm EDT | Craig A JohnsonDirector | 50,000 | — | — | 50,000 | — | |
| Aug 10, 2016 MForm 4 → | Aug 12, 5:14 pm EDT | Robert RosenPresident & CCO, Director | 100,000 | — | — | 825,000 | — | |
| Jul 19, 2016 MForm 4 → | Jul 20, 8:50 am EDT | Barry D QuartChief Executive Officer, Director | 4,630 | — | — | 930,277 | — | |
| Jun 22, 2016 AForm 4 → | Jun 23, 10:34 am EDT | Craig A JohnsonDirector | 1,000 | — | — | 1,000 | — | |
| Jun 22, 2016 AForm 4 → | Jun 23, 10:31 am EDT | Waage ChristianDirector | 26,500 | — | — | 1,500 | — | |
| Jun 16, 2016 MForm 4 → | Jun 20, 8:01 pm EDT | Kevin C Tang +2Director, 10% Owner | 1,250,000 | — | — | 0 | — | |
| Apr 19, 2016 MForm 4 → | Apr 21, 9:27 pm EDT | Robert RosenPresident, Director | 200,000 | — | — | 925,000 | — | |
| Mar 21, 2016 MForm 4 → | Mar 23, 3:07 pm EDT | Paul MarshallSVP, Technical Operations | 1,100 | — | — | 42,800 | — | |
| Mar 2, 2016 MForm 4 → | Mar 3, 8:01 am EST | Barry D QuartChief Executive Officer, Director | 3,472 | — | — | 934,907 | — | |
| Jan 28, 2016 AForm 4 → | Jan 29, 8:19 pm EST | Kimberly ManhardExecutive VP, Drug Development | 300,000 | — | — | 300,000 | — | |
| Dec 29, 2015 MForm 4 → | Dec 30, 5:14 pm EST | Paul MarshallSVP, Technical Operations | 1,100 | — | — | 43,900 | — | |
| Dec 28, 2015 MForm 4 → | Dec 30, 5:13 pm EST | Barry D QuartChief Executive Officer, Director | 2,315 | — | — | 938,379 | — | |
| Dec 22, 2015 AForm 4 → | Dec 24, 1:03 pm EST | Kevin C TangDirector, 10% Owner | 17,000 | — | — | 17,000 | — | |
| Dec 22, 2015 AForm 4 → | Dec 24, 12:39 pm EST | John PoyhonenDirector | 19,500 | — | — | 19,500 | — | |
| Dec 22, 2015 AForm 4 → | Dec 24, 12:38 pm EST | Kimberly ManhardDirector | 19,000 | — | — | 19,000 | — | |
| Dec 22, 2015 AForm 4 → | Dec 24, 12:34 pm EST | Craig A JohnsonDirector | 19,000 | — | — | 19,000 | — | |
| Dec 22, 2015 AForm 4 → | Dec 24, 12:32 pm EST | Robert RosenPresident, Director | 250,000 | — | — | 250,000 | — | |
| Dec 22, 2015 AForm 4 → | Dec 24, 12:31 pm EST | Barry D QuartChief Executive Officer, Director | 250,000 | — | — | 250,000 | — | |
| Dec 22, 2015 AForm 4 → | Dec 24, 12:30 pm EST | Paul MarshallSVP, Technical Operations | 50,000 | — | — | 50,000 | — | |
| Dec 22, 2015 AForm 4 → | Dec 24, 12:29 pm EST | Brian G. DrazbaVP, Finance & CFO | 50,000 | — | — | 50,000 | — | |
| Oct 14, 2015 MForm 4 → | Oct 15, 8:02 am EDT | Barry D QuartChief Executive Officer, Director | 10,000 | — | — | 940,694 | — | |
| Oct 12, 2015 AForm 4 → | Oct 13, 9:21 pm EDT | Neil James ClendeninnSVP & Chief Medical Officer | 150,000 | — | — | 50,000 | — | |
| Sep 29, 2015 MForm 4 → | Sep 30, 8:51 am EDT | Barry D QuartChief Executive Officer, Director | 14,306 | — | — | 950,694 | — | |
| Aug 18, 2015 MForm 4 → | Aug 19, 4:39 pm EDT | Barry D QuartChief Executive Officer, Director | 10,000 | — | — | 965,000 | — | |
| Jun 1, 2015 MForm 4 → | Jun 3, 6:46 pm EDT | Kimberly ManhardDirector | 13,208 | — | — | 21,000 | — | |
| Mar 5, 2015 MForm 4 → | Mar 9, 7:02 pm EDT | Paul MarshallSVP, Technical Operations | 70,000 | — | — | 140,000 | — |